transmembrane protein 233Genealiases: DSPB2 · IFITMD2
Q-omics provides the consensus-scored TMEM233 profile across patient tissues and cancer cell-line models. TMEM233 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM233 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM233 RNA expression shows 19,807 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where TMEM233 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM233 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM233 survival associations across molecular data types. TMEM233 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM233 RNA expression–survival associations across cancer types. High TMEM233 expression shows unfavorable associations in STAD, UVM and LUSC, but favorable associations in KIRC, KICH and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM233 RNA expression.
This table summarizes TMEM233 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM233. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM233 shows lower tumor expression in BLCA and LUSC and higher tumor expression in KIRC, STAD, LIHC and BRCA. The KIRC box plot shows higher TMEM233 RNA expression in tumor versus normal tissue (log2 FC = +1.825, t-test p < 0.001).
This table shows molecular features associated with TMEM233 in patient tissues and cancer cell lines. In patient samples, TMEM233 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM233 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
